View Bio-Rad Laboratories, Inc. Class A BIO stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

On Wednesday, Bio-Rad Labs ABIO got an upgrade to its Relative Strength (RS) Rating, from 69 to 72. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The Day How ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

We recently published a list of Billionaire Mason Hawkins’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) ...

Bio-Rad Laboratories, Inc. BIO posted first-quarter 2025 adjusted earnings per share (EPS) of $2.54, which surpassed the Zacks Consensus Estimate of $1.73 by 46.8%. The bottom line increased 10.9% ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life ...